JVM Completes Suzhou Production Base in China, Expands Global Footprint

Production Hub for Automated Pharmaceutical Dispensing Equipment

JVM, a company specializing in pharmacy automation, has established a production base in Suzhou, China, accelerating the localization of its production system to target the global market.

JVM China Factory Completion Ceremony. Hanmi Group

JVM, a subsidiary of Hanmi Science, announced on May 15 that it has built a new factory for manufacturing pharmaceutical automatic dispensing equipment in the Suzhou Industrial Park, a joint development zone between China and Singapore. The company held a completion ceremony for the factory last month.

This new production base is part of the global manufacturing expansion strategy outlined at last year’s Hanmi Group Vision Day. It represents a strategic investment to strengthen supply chain competitiveness and production efficiency by securing a local manufacturing base in China.

China is a rapidly growing market for pharmacy automation, driven by an aging population and the advancement of medical infrastructure. Through this production base, JVM plans to accelerate its response to local market needs and intensify its efforts to capture the automated dispensing market in China.

The production facility will manufacture JVM’s APS equipment (300NS, 360NS, 420NS, 480NS), an automated pharmaceutical sorting and packaging system. APS is a core device that supports dispensing automation for hospitals, clinics, and pharmacies. Demand for APS continues to rise in line with the expansion of the global medical automation market.

The company explained that the production base’s location within Suzhou Industrial Park allows it to leverage both an excellent manufacturing environment and a specialized medical industry ecosystem. Suzhou Industrial Park is one of China’s leading advanced industrial complexes, home to a concentration of foreign-invested companies, and offers a stable business environment and robust production infrastructure.

JVM aims to use this base to improve accessibility to the Chinese market, expand local product supply and technical support, and enhance delivery responsiveness, supply efficiency, and price competitiveness. Going forward, the company plans to gradually increase its capabilities in sourcing parts and materials, develop the site into a production hub for Asia, and further improve the efficiency of its global supply chain operations.

JVM is also continuing its global business expansion, focusing on the North American and European markets. In North America, the company has launched its robot-based automatic dispensing equipment, COUNTMATE, and in Europe, it is expanding its sales and supply network through local subsidiaries and partners.

The next-generation robotic dispensing equipment, MENITH, completed enhancements to its inspection functions in the fourth quarter of last year. By launching new equipment and expanding its product portfolio, JVM is also accelerating its expansion into healthcare and software sectors by integrating artificial intelligence (AI) and robotics technologies with its automated dispensing expertise.

Meanwhile, JVM is recognized as an industry leader in automated dispensing equipment, renowned for its R&D-driven innovation and technological capabilities. Approximately 30% of its total workforce is engaged in R&D, and the company consistently invests around 7% of its annual standalone revenue in research and development. Hanmi Pharmaceutical and Online Pharm are responsible for JVM’s overseas and domestic businesses, respectively, while Hanmi Group supplies JVM equipment to 35 global partners in 60 countries worldwide.

JVM CEO Kim Sangwook stated, “The China production base is a key hub for strengthening our global supply chain competitiveness and local responsiveness. We will continue to expand our presence not only in China and Asia but also in North America and Europe, further solidifying our position in the global automated dispensing market by enhancing our product and technology competitiveness.”

This content was produced with the assistance of AI translation services.